Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roth, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roth, A. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:175-177, 2003
© 2003 European Society for Medical Oncology

Editorial

Chemotherapy in gastric cancer: a never ending saga

A. D. Roth

Oncosurgery, Department of Surgery, Geneva University Hospital, 24 Micheli-du-Crest, CH-1211 Geneva 14, Switzerland (E-mail: arnaud.roth@dim.hcuge.ch)

The first 10% of the full text of this article appears below.

For a long period of time, gastric carcinoma was considered to be a poorly chemoresponsive tumor. Before the CT-scan era, clinical investigations were not reliable by today’s standards because of the paucity of good radiological tools, and because patients without measurable disease were also enrolled. The so-called ‘first-generation’ drug combinations, designed before the introduction of cisplatin to the treatment of this disease, gave disappointing results [1–4]. The combination of mitomycin C, doxorubicin and 5-fluorouracil (5-FU) (FAM) was considered a standard for more than a decade.

In the late 1980s, attempts were made to increase the efficacy of chemotherapy by designing more intensive regimens. The combination of 5-FU–doxorubicin–methotrexate (FAMTX) with high-dose methotrexate (MTX) and leucovorin (LCV) rescue was . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?